Key Findings: The State of Metabolic Health in America, 2026
This page summarizes the key findings from each of the ten series in the 2026 Baseline Edition. Each finding is a standalone, quotable statement with the value, population, year, and primary source. Each links to its individual metric page for the full definition, source citation, and methodological notes.
Findings are organized by series in report order. Where two sources report different figures for the same condition, both are documented on the metric page rather than reconciled here.
For the complete list of all 98 metrics with values and sources, see the All Metrics index. For what the data do not show, see Data Gaps.
America's Metabolic Health (MH)
Adult obesity prevalence was 40.3% in 2023, among u.s. adults.
Source: CDC, National Center for Health Statistics (NCHS), 2023. Metric MH-01 →
Severe obesity prevalence (BMI ≥ 40) was 9.7% in 2017–2020, among u.s. adults.
Source: CDC, NHANES, 2017–2020. Metric MH-02 →
Adults with diagnosed or undiagnosed diabetes was More than 40 million in 2024, among u.s. adults.
Source: CDC, National Diabetes Statistics Report, 2024. Metric MH-03 →
Adults with prediabetes was More than 115 million in 2024, among u.s. adults.
Source: CDC, National Diabetes Statistics Report, 2024. Metric MH-04 →
Adult hypertension prevalence (measured) was 47.7% in 2023, among u.s. adults.
Source: CDC, NHANES, 2023. Metric MH-05 →
Adults with chronic kidney disease unaware of diagnosis was ~90% in 2024, among u.s. adults with ckd.
Source: National Kidney Foundation / CDC, 2024. Metric MH-06 →
Metabolic syndrome prevalence was 38.5% in 2023, among u.s. adults.
Source: CDC, NHANES, 2023. Metric MH-07 →
Adults with diabetes who also have CKD was ~38% in 2026, among u.s. adults with diagnosed or undiagnosed diabetes.
Source: CDC, March 2026 estimates, 2026. Metric MH-08 →
Adults with hypertension who also have CKD was ~21% in 2026, among u.s. adults with hypertension.
Source: CDC, March 2026 estimates, 2026. Metric MH-09 →
Adults with prediabetes who also have CKD was ~11% in 2026, among u.s. adults with prediabetes.
Source: CDC, March 2026 estimates, 2026. Metric MH-10 →
Economic Impact (EI)
U.S. national health expenditures was $5.3 trillion in 2024, among united states.
Source: CMS, National Health Expenditure Accounts, 2024. Metric EI-01 →
Total economic cost of diagnosed diabetes was $412.9 billion in 2022, among u.s. adults with diagnosed diabetes.
Source: American Diabetes Association, 2022. Metric EI-02 →
Direct medical costs of diagnosed diabetes was $306.6 billion in 2022, among u.s. adults with diagnosed diabetes.
Source: American Diabetes Association, 2022. Metric EI-03 →
Indirect costs of diagnosed diabetes (lost productivity) was $106.3 billion in 2022, among u.s. adults with diagnosed diabetes.
Source: American Diabetes Association, 2022. Metric EI-04 →
Annual illness-related lost productivity for U.S. employers was $575 billion in 2024, among u.s. employers.
Source: Integrated Benefits Institute, 2024. Metric EI-05 →
Diabetes- and hypertension-related mortality, rural adults was 85.6 in 2020, among rural adults aged 25 and older.
Source: CDC, 2020. Metric EI-06 →
Diabetes- and hypertension-related mortality, urban adults was 71.7 in 2020, among urban adults aged 25 and older.
Source: CDC, 2020. Metric EI-07 →
Adult obesity prevalence, Black adults was 49.9% in 2024, among black non-hispanic adults.
Source: CDC, BRFSS, 2024. Metric EI-08 →
Adult obesity prevalence, Hispanic adults was 45.6% in 2024, among hispanic adults.
Source: CDC, BRFSS, 2024. Metric EI-09 →
Adult obesity prevalence, white adults was 41.4% in 2024, among white non-hispanic adults.
Source: CDC, BRFSS, 2024. Metric EI-10 →
Employer Healthcare (EH)
Average employer-sponsored family health insurance premium was $26,993 in 2025, among employer-sponsored family coverage.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-01 →
Average worker contribution toward family coverage was $6,850 in 2025, among workers enrolled in employer-sponsored family coverage.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-02 →
Average worker contribution toward single coverage was $1,440 in 2025, among workers enrolled in employer-sponsored single coverage.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-03 →
Average employer health benefit cost per employee was $17,496 in 2025, among employer-sponsored coverage.
Source: Mercer National Survey of Employer-Sponsored Health Plans 2025, 2025. Metric EH-04 →
Projected employer health benefit cost increase was 6.7% in 2026 projection, among employer-sponsored coverage.
Source: Mercer National Survey of Employer-Sponsored Health Plans 2025, 2026 projection. Metric EH-05 →
Prescription drug spending increase, large employers was 9.4% in 2025, among employers with 500 or more employees.
Source: Mercer National Survey of Employer-Sponsored Health Plans 2025, 2025. Metric EH-06 →
Workers at large firms enrolled in self-funded plans was 80% in 2025, among covered workers at firms with 200 or more workers.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-07 →
Mid-size employers covering GLP-1s for weight loss was 19% in 2025, among firms with 200 or more workers.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-08 →
Large employers covering GLP-1s for weight loss was 43% in 2025, among firms with 5,000 or more workers.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-09 →
Large employers requiring lifestyle program for GLP-1 coverage was 34% in 2025, among firms with 200+ workers that cover glp-1s for weight loss.
Source: KFF Employer Health Benefits Survey 2025, 2025. Metric EH-10 →
Medicare (MA)
Medicare beneficiaries with diagnosed diabetes (ASPE analysis) was 26% in 2024, among medicare beneficiaries.
Source: ASPE (HHS Office of the Assistant Secretary for Planning and Evaluation), 2024. Metric MA-01 →
Medicare beneficiaries with diagnosed diabetes (claims-based) was ~20% in 2024, among medicare beneficiaries.
Source: CMS administrative data, 2024. Metric MA-02 →
Medicare Diabetes Prevention Program active participants was 941 in Most recently published count, among medicare beneficiaries with prediabetes.
Source: CMS, Most recently published count. Metric MA-03 →
Prediabetes prevalence among adults aged 65 and older was 52.1% in 2024, among u.s. adults aged 65 and older.
Source: CDC, National Diabetes Statistics Report, 2024. Metric MA-04 →
Medicare Advantage plans offering food and produce benefits was 11% in 2026, among individual medicare advantage plans.
Source: CMS Medicare Advantage plan data, 2026. Metric MA-05 →
Special Needs Plans offering food and produce benefits was 85% in 2026, among medicare special needs plans.
Source: CMS Medicare Advantage plan data, 2026. Metric MA-06 →
Medicare Advantage plans offering general supports for living was 8% in 2026, among individual medicare advantage plans.
Source: CMS Medicare Advantage plan data, 2026. Metric MA-07 →
Medicare Advantage plans offering non-medical transportation was 5% in 2026, among individual medicare advantage plans.
Source: CMS Medicare Advantage plan data, 2026. Metric MA-08 →
ACCESS model launch date was July 5, 2026 in 2026, among voluntary medicare participants.
Source: CMS Innovation Center, 2026. Metric MA-09 →
ACCESS model maximum payment reduction for underperformance was 50% in 2026, among access model participants.
Source: CMS Innovation Center, 2026. Metric MA-10 →
Medicaid (MD)
Medicaid and CHIP enrollment was 74.3 million in March 2026, among medicaid and chip enrollees.
Source: CMS Medicaid enrollment data, March 2026. Metric MD-01 →
Medicaid enrollment one year prior was 78.6 million in March 2025, among medicaid and chip enrollees.
Source: CMS Medicaid enrollment data, March 2025. Metric MD-02 →
Nonelderly Medicaid adults with cardiometabolic multimorbidity was 29.7% in 2024, among nonelderly medicaid adults.
Source: KFF analysis of Medicaid data, 2024. Metric MD-03 →
Nonelderly Medicaid adults with exactly one cardiometabolic condition was 29.3% in 2024, among nonelderly medicaid adults.
Source: KFF analysis of Medicaid data, 2024. Metric MD-04 →
State Medicaid fee-for-service programs covering GLP-1s for obesity was 13 in January 2026, among state medicaid fee-for-service programs.
Source: KFF Medicaid coverage tracker, January 2026. Metric MD-05 →
State Medicaid programs covering GLP-1s for obesity (October 2025) was 16 in October 2025, among state medicaid fee-for-service programs.
Source: KFF Medicaid coverage tracker, October 2025. Metric MD-06 →
States with approved Medicaid waivers addressing health-related social needs was 25 in 2026, among state medicaid programs.
Source: CMS Section 1115 waiver approvals, 2026. Metric MD-07 →
NC Healthy Opportunities Pilots: estimated savings per member per month was $164 in 2026, among 31,597 nc medicaid enrollees in healthy opportunities pilots.
Source: UNC Cecil G. Sheps Center for Health Services Research, June 2026 summative evaluation, 2026. Metric MD-08 →
NC Healthy Opportunities Pilots: total federal Medicaid funding authorized was $650 million in 2019–2024, among nc medicaid enrollees.
Source: CMS Section 1115 waiver authorization, 2019–2024. Metric MD-09 →
NC Healthy Opportunities Pilots: enrollees in summative evaluation was 31,597 in 2026, among nc medicaid enrollees in healthy opportunities pilots.
Source: UNC Cecil G. Sheps Center for Health Services Research, June 2026 summative evaluation, 2026. Metric MD-10 →
Public Health Infrastructure and Prevention (PH)
Adult obesity prevalence, Colorado (lowest state) was 25.0% in 2024, among colorado adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-01 →
Adult obesity prevalence, West Virginia (highest state) was 41.4% in 2024, among west virginia adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-02 →
Adult obesity prevalence, Mississippi was 40.4% in 2024, among mississippi adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-03 →
Adult obesity prevalence, Louisiana was 39.2% in 2024, among louisiana adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-04 →
Adult obesity prevalence, Midwest region was 35.9% in 2024, among midwest adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-05 →
Adult obesity prevalence, South region was 34.5% in 2024, among south adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-06 →
Adult obesity prevalence, West region was 30.2% in 2024, among west adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-07 →
Adult obesity prevalence, Northeast region was 30.3% in 2024, among northeast adults.
Source: CDC, BRFSS 2024, 2024. Metric PH-08 →
Diagnosed diabetes prevalence, rural adults was 12.3% in 2024, among rural u.s. adults.
Source: CDC, National Health Interview Survey (NHIS), 2024. Metric PH-09 →
Diagnosed diabetes prevalence, urban adults was 9.3% in 2024, among urban u.s. adults.
Source: CDC, National Health Interview Survey (NHIS), 2024. Metric PH-10 →
State-by-State Variation (SV)
Self-reported hypertension prevalence, Colorado (lowest state) was 24.6% in 2021, among colorado adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-01 →
Self-reported hypertension prevalence, Mississippi (highest state) was 40.6% in 2021, among mississippi adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-02 →
National self-reported hypertension prevalence (age-standardized) was 30.1% in 2021, among u.s. adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-03 →
Rural diagnosed diabetes prevalence, Colorado (lowest state) was 8.4% in 2021, among rural colorado adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-04 →
Rural diagnosed diabetes prevalence, North Carolina (highest state) was 21.3% in 2021, among rural north carolina adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-05 →
Urban diagnosed diabetes prevalence, Colorado (lowest state) was 6.9% in 2021, among urban colorado adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-06 →
Urban diagnosed diabetes prevalence, West Virginia (highest state) was 15.5% in 2021, among urban west virginia adults.
Source: CDC, BRFSS 2021, 2021. Metric SV-07 →
Adult obesity prevalence, Asian adults was 16.1% in 2024, among asian non-hispanic adults.
Source: CDC, BRFSS 2024, 2024. Metric SV-08 →
States where every adult has obesity prevalence of at least 25% was 50 of 50 in 2024, among all u.s. states.
Source: CDC, BRFSS 2024, 2024. Metric SV-09 →
South census region diabetes/hypertension mortality rank was Highest in 2020, among adults aged 25 and older.
Source: CDC, 2020. Metric SV-10 →
Medicaid Innovation (MI)
NC Healthy Opportunities Pilots: emergency department visit reduction was Statistically significant reduction in 2026, among 31,597 nc medicaid enrollees.
Source: UNC Cecil G. Sheps Center, June 2026 summative evaluation, 2026. Metric MI-01 →
NC Healthy Opportunities Pilots: effect on hemoglobin A1c was No statistically significant effect in 2026, among nc medicaid enrollees in healthy opportunities pilots.
Source: UNC Cecil G. Sheps Center, June 2026 summative evaluation, 2026. Metric MI-02 →
NC Healthy Opportunities Pilots: effect on blood pressure was No statistically significant effect in 2026, among nc medicaid enrollees in healthy opportunities pilots.
Source: UNC Cecil G. Sheps Center, June 2026 summative evaluation, 2026. Metric MI-03 →
NC Healthy Opportunities Pilots: Section 1115 waiver authorization year was 2019 in 2019, among nc medicaid program.
Source: CMS Section 1115 waiver records, 2019. Metric MI-04 →
States with Medicaid Section 1115 waivers for health-related social needs was 25 in 2026, among state medicaid programs.
Source: CMS Section 1115 waiver approvals, 2026. Metric MI-05 →
Medicaid GLP-1 obesity coverage: states that eliminated benefit (Oct 2025–Jan 2026) was 4 in October 2025–January 2026, among state medicaid fee-for-service programs.
Source: KFF Medicaid coverage tracker, October 2025–January 2026. Metric MI-06 →
Medicaid cardiometabolic multimorbidity burden (2+ conditions) was 29.7% in 2024, among nonelderly medicaid adults.
Source: KFF analysis of Medicaid data, 2024. Metric MI-07 →
Medicaid enrollment decline (March 2025 to March 2026) was 4.3 million in March 2025–March 2026, among medicaid and chip enrollees.
Source: CMS Medicaid enrollment data, March 2025–March 2026. Metric MI-08 →
NC Healthy Opportunities Pilots: hospital stay reduction was Statistically significant reduction in 2026, among 31,597 nc medicaid enrollees.
Source: UNC Cecil G. Sheps Center, June 2026 summative evaluation, 2026. Metric MI-09 →
NC Healthy Opportunities Pilots: shift to lower-cost settings was More visits to outpatient and primary care in 2026, among 31,597 nc medicaid enrollees.
Source: UNC Cecil G. Sheps Center, June 2026 summative evaluation, 2026. Metric MI-10 →
Medicare Innovation (MV)
ACCESS model: clinical tracks addressing metabolic health was 2 of 4 in 2026, among access model participants.
Source: CMS Innovation Center, 2026. Metric MV-01 →
ACCESS model: payment tied to biomarker achievement was Up to 50% in 2026, among access model participants.
Source: CMS Innovation Center, 2026. Metric MV-02 →
ACCESS model: minimum beneficiary target for full payment (Year 1) was 50% in 2026, among access model participants.
Source: CMS Innovation Center, 2026. Metric MV-03 →
ACCESS model: planned duration was 10 years in 2026–2036, among voluntary medicare participants.
Source: CMS Innovation Center, 2026–2036. Metric MV-04 →
Medicare Diabetes Prevention Program: active participants vs. eligible population was 941 vs. ~31.3 million in Most recently published count, among medicare beneficiaries with prediabetes aged 65+.
Source: CMS; CDC National Diabetes Statistics Report, Most recently published count. Metric MV-05 →
ACCESS model: required biomarker measure categories was 5 in 2026, among access model participants.
Source: CMS Innovation Center, 2026. Metric MV-06 →
Medicare beneficiaries with diagnosed diabetes (approximate count) was ~17.7 million in 2024, among medicare beneficiaries.
Source: ASPE analysis, 2024. Metric MV-07 →
Special Needs Plans offering general supports for living was 72% in 2026, among medicare special needs plans.
Source: CMS Medicare Advantage plan data, 2026. Metric MV-08 →
Special Needs Plans offering non-medical transportation was 36–37% in 2026, among medicare special needs plans.
Source: CMS Medicare Advantage plan data, 2026. Metric MV-09 →
ACCESS model: participation type was Voluntary in 2026, among eligible medicare organizations.
Source: CMS Innovation Center, 2026. Metric MV-10 →
Employer Innovation (EN)
Large employers likely to continue GLP-1 coverage in 2027 (BGH survey) was 72% in 2026, among large employers already covering glp-1 treatment.
Source: Business Group on Health 2026 survey (105 large-employer members), 2026. Metric EN-01 →
Large employers unlikely to continue GLP-1 coverage in 2027 (BGH survey) was 10% in 2026, among large employers already covering glp-1 treatment.
Source: Business Group on Health 2026 survey, 2026. Metric EN-02 →
Large employers intending to maintain GLP-1 coverage (WTW survey) was 70% in June 2026, among wtw client employers (294 clients, 2.8m+ plan members).
Source: WTW June 2026 survey, June 2026. Metric EN-03 →
Large employers likely or very likely to discontinue GLP-1 coverage (WTW) was 12% in June 2026, among wtw client employers.
Source: WTW June 2026 survey, June 2026. Metric EN-04 →
Large employers somewhat likely to discontinue GLP-1 coverage (WTW) was 18% in June 2026, among wtw client employers.
Source: WTW June 2026 survey, June 2026. Metric EN-05 →
Employers that dropped GLP-1 coverage in 2026 (Mercer) was 6% in 2026, among employers previously covering glp-1 medications.
Source: Mercer National Survey of Employer-Sponsored Health Plans 2025, 2026. Metric EN-06 →
Employers that tightened GLP-1 utilization controls in 2026 (Mercer) was 27–30% in 2026, among employers covering glp-1 medications.
Source: Mercer National Survey of Employer-Sponsored Health Plans 2025, 2026. Metric EN-07 →
IFEBP survey: employers covering GLP-1s for both diabetes and weight loss was 36% in 2025, among international foundation of employee benefit plans survey respondents.
Source: International Foundation of Employee Benefit Plans survey, 2025. Metric EN-08 →
BGH survey: large employers with weight-management GLP-1 coverage was 67% in 2026, among business group on health large-employer members (105 respondents).
Source: Business Group on Health 2026 survey, 2026. Metric EN-09 →
WTW survey: employers with weight-management GLP-1 coverage was 66% in 2026, among wtw clients (294 clients, 2.8m+ plan members).
Source: WTW 2026 survey, 2026. Metric EN-10 →
What the Data Do Not Show
The 2026 Baseline Edition names what is not measured rather than estimating missing values. Key gaps include longitudinal tracking of metabolic health improvement at the population level, consistent state-level data on GLP-1 medication outcomes, and clinical outcome data from newly launched payment models such as the CMS ACCESS model.
See Data Gaps for the full list of documented gaps, the affected metrics, and what data collection changes would close them.